episode 1072: Clinical update with Dr. Daniel Griffin
In his weekly clinical update Dr. Griffin discusses the annual economic burden of respiratory syncytial virus in adults in the US, recombinant or standard-dose influenza vaccine in adults under 65 years of age, maternal vaccine effectiveness against influenza-associated hospitalizations and emergency department visits in iInfants, influenza positive tests reported to CDC by US clinical laboratories, update on COVID-19, risk of severe maternal morbidity associated with SARS-CoV-2 infection during pregnancy, COVID-19 rapid antigen tests with self-collected vs health care worker–collected nasal and throat swab specimens, optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation, long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study, and risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- RSV economic burden, US (J Inf Dis)
- Recombinant or standard dose influenza vaccine (NEJM)
- Maternal vaccine effectiveness against influenza in Infants (JAMA Ped)
- Weekly influenza surveillance report (MMWR)
- COVID data tracker (hospital admissions, national trend)
- Risk of severe maternal morbidity associated with SARS-CoV-2 infection (J Inf Dis)
- COVID-19 rapid antigen tests with nasal and throat swab specimens (JAMA Net Open)
- Optimal timing of nirmatrelvir/ritonavir (Nat Comm)
- Long-term outcomes following hospital admission for COVID-19 vs influenza (Lancet)
- Contribute to our MicrobeTV fundraiser at PWB
- Letters read on TWiV 1072
- Dr. Griffin’s COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv